PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cancer Therapeutics CRC Pty Ltd

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cancer ranks #34,644 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.

#34,644
of 49,997 US assignees by volume
26th percentile
by Innovation Score (28.2/100)
24.9
avg claims per patent
-100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R34644 · Foreign Corporation #34,644 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 7 grants
  • MID-PACK #34,644/49,997
  • PHOTO-FINISH Callsign
  • CPC-NARROW A61P · 3 areas
  • INNOV-THIN 28.2/100
  • CLAIMS-DENSE 24.9 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Callsign Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cancer’s 28.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Cancer

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Cancer's Innovation Score is 28.2/100 (26th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Cancer?

Each dot is one of Cancer’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cancer’s own 24.9 claims/patent is ABOVE the 11.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cancer vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 6.97.07.077.07.07.1 0102030 Granted patents (volume) Avg claims / patent Callsign Inc. - 7, 25.57CallsignCamcon Auto Limited - 7, 14.57Camcon AutoCan Do Logistics LLC - 7, 8.14Can Do LogisticsCanada Pooch Ltd. - 7, 3.57Canada PoochCandi Controls, Inc. - 7, 20.14Candi ControlsCantex International, Inc. - 7, 27.14Cantex Internatio…Cap Barbell, Inc. - 7, 11.29Cap BarbellCapitol AI, Inc. - 7, 9.29Capitol AICancer Therapeutics CRC Pty Ltd - 7, 24.86Cancer Therapeuti…
Cancer vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cancer's grants concentrate

Cancer Therapeutics CRC Pty Ltd is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2018. By volume, Cancer sits between Callsign Inc. and Capitol AI, Inc..

Who files at Cancer's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Cancer holds 7 patents at rank #34,770, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Cancer

By rank, the assignees closest to #34,770 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Cancer's primary technology class.

Cancer's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 26th percentile higher than 26% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201520162018 1
USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Cancer Therapeutics CRC Pty Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 3 42.9%
2016 3 42.9%
2018 1 14.3%

Which technologies does Cancer Therapeutics CRC Pty Ltd patent most?

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cancer Therapeutics CRC Pty Ltd's patent record in context - here's where to go next.

  • Cancer Therapeutics CRC Pty Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #34,644 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Cancer Therapeutics CRC Pty Ltd against Callsign Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 28.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.